PRAXIS PRECISION MEDICINES, INC. Investing Cash Flow
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Investing Cash Flow of -$333.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $10.98M, a 38.63% decline year-over-year.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$344.27M.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$328.39M.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $50.41M, a 1.71% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$311.15M.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$248.49M, a 737.98% decline from fiscal 2023.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) investing activities for fiscal 2023 was $38.95M, a 59.80% decline from fiscal 2022.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) investing activities for fiscal 2022 was $96.89M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$333.29M 10-Q · filed 2026-08-06 | -$661.68M derived: sum of 3 quarters · filed 2026-08-06 | -$611.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$344.27M 10-Q · filed 2026-05-07 | -$672.67M derived: sum of 2 quarters · filed 2026-05-07 | -$622.25M derived: sum of 3 quarters · filed 2026-05-07 | -$604.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$328.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$277.98M derived: sum of 2 quarters · filed 2026-02-19 | -$260.08M derived: sum of 3 quarters · filed 2026-08-06 | -$311.15M 10-K · filed 2026-02-19 |
| 2025-09-30 | $50.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $68.31M derived: sum of 2 quarters · filed 2026-08-06 | $17.24M 10-Q · filed 2025-11-05 | $6.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $17.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$33.17M 10-Q · filed 2026-08-06 | -$44.09M derived: sum of 3 quarters · filed 2026-08-06 | $5.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$51.06M 10-Q · filed 2026-05-07 | -$61.98M derived: sum of 2 quarters · filed 2026-05-07 | -$12.42M derived: sum of 3 quarters · filed 2026-05-07 | -$208.34M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$10.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $38.65M derived: sum of 2 quarters · filed 2026-02-19 | -$157.27M derived: sum of 3 quarters · filed 2026-02-19 | -$248.49M 10-K · filed 2026-02-19 |
| 2024-09-30 | $49.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$146.36M derived: sum of 2 quarters · filed 2025-11-05 | -$237.58M 10-Q · filed 2025-11-05 | -$237.63M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$195.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | -$287.14M 10-Q · filed 2025-08-04 | -$287.19M derived: sum of 3 quarters · filed 2026-02-19 | -$287.19M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$91.22M 10-Q · filed 2025-05-02 | -$91.27M derived: sum of 2 quarters · filed 2026-02-19 | -$91.27M derived: sum of 3 quarters · filed 2026-02-19 | -$86.27M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$50.00K derived: sum of 2 quarters · filed 2026-02-19 | $4.95M derived: sum of 3 quarters · filed 2026-02-19 | $38.95M 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $5.00M derived: sum of 2 quarters · filed 2024-11-06 | $39.00M 10-Q · filed 2024-11-06 | $61.59M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $39.00M 10-Q · filed 2024-08-13 | $61.59M derived: sum of 3 quarters · filed 2024-08-13 | $109.55M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $34.00M 10-Q · filed 2024-05-13 | $56.59M derived: sum of 2 quarters · filed 2024-05-13 | $104.55M derived: sum of 3 quarters · filed 2024-05-13 | $139.44M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $22.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $70.55M derived: sum of 2 quarters · filed 2024-03-05 | $105.44M derived: sum of 3 quarters · filed 2024-03-05 | $96.89M 10-K · filed 2024-03-05 |
| 2022-09-30 | $47.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $82.84M derived: sum of 2 quarters · filed 2023-11-07 | $74.30M 10-Q · filed 2023-11-07 | $84.46M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $34.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $26.34M 10-Q · filed 2023-08-09 | $36.51M derived: sum of 3 quarters · filed 2023-08-09 | $50.06M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$8.55M 10-Q · filed 2023-05-11 | $1.62M derived: sum of 2 quarters · filed 2023-05-11 | $15.17M derived: sum of 3 quarters · filed 2023-05-11 | -$9.06M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $10.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $23.72M derived: sum of 2 quarters · filed 2023-02-07 | -$510.00K derived: sum of 3 quarters · filed 2023-02-07 | -$140.52M 10-K · filed 2023-02-07 |
| 2021-09-30 | $13.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$10.68M derived: sum of 2 quarters · filed 2022-11-09 | -$150.69M 10-Q · filed 2022-11-09 | -$150.69M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$24.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$164.24M 10-Q · filed 2022-08-08 | -$164.24M derived: sum of 3 quarters · filed 2022-08-08 | -$164.24M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$140.01M 10-Q · filed 2022-05-09 | -$140.01M derived: sum of 2 quarters · filed 2022-05-09 | -$140.01M derived: sum of 3 quarters · filed 2022-05-09 | -$140.01M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | $0.00 derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $0.00 10-Q · filed 2021-08-16 | $0.00 derived: sum of 3 quarters · filed 2021-08-16 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | -$103.00K 10-K · filed 2021-03-17 | ||
| 2019-09-30 | -$103.00K 10-Q · filed 2020-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |